Literature DB >> 12161529

A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length.

S Dejager1, H Bry-Gauillard, E Bruckert, B Eymard, F Salachas, E LeGuern, S Tardieu, R Chadarevian, P Giral, G Turpin.   

Abstract

Our study aims to provide a comprehensive view of the endocrine features in Kennedy's disease (KD). Twenty-two men with KD underwent detailed endocrine investigations. Clinical signs of partial androgen resistance were present in more than 80% of the patients, with gynecomastia being the most prominent. Gynecomastia was postpubertal but appeared before muscular weakness in most cases. Thirteen patients had alteration of testicular exocrine function. Hormonal profile of partial androgen resistance was present in 86% of the patients, with an elevated testosterone level in 68%. Androgen insensitivity seems to appear later in life in KD, similar to the development of neurological signs. Although we confirm the previously reported correlation between the CAG repeat length and the early onset of the neurological disease, we describe a significant correlation between repeat length and the age of onset of gynecomastia as well as biological indexes of androgen insensitivity. This is supported by numerous in vitro data correlating variations in the CAG tract with androgen receptor activity; the longer the CAG repeats, the weaker the receptor transactivation. Ours is the first study to show such a clear and prominent pattern of androgen insensitivity in KD. In clinical practice, KD patients are often misdiagnosed as having amyotrophic lateral sclerosis. Careful examination of the endocrine component could avoid such a deleterious misdiagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161529     DOI: 10.1210/jcem.87.8.8780

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Authors:  Sara Lindström; Jing Ma; David Altshuler; Edward Giovannucci; Elio Riboli; Demetrius Albanes; Naomi E Allen; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Stephen J Chanock; Alison M Dunning; Heather Spencer Feigelson; J Michael Gaziano; Christopher A Haiman; Richard B Hayes; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Loic Le Marchand; Carmen Martínez; Kim Overvad; Afshan Siddiq; Meir Stampfer; Pär Stattin; Daniel O Stram; Michael J Thun; Dimitrios Trichopoulos; Rosario Tumino; Jarmo Virtamo; Stephanie J Weinstein; Meredith Yeager; Peter Kraft; Matthew L Freedman
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  Evaluation of breast enlargement in young males and factors associated with gynecomastia and pseudogynecomastia.

Authors:  M Yazici; M Sahin; E Bolu; D E Gok; A Taslipinar; S Tapan; D Torun; G Uckaya; M Kutlu
Journal:  Ir J Med Sci       Date:  2009-06-04       Impact factor: 1.568

3.  Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy.

Authors:  Hideaki Nakatsuji; Amane Araki; Atsushi Hashizume; Yasuhiro Hijikata; Shinichiro Yamada; Tomonori Inagaki; Keisuke Suzuki; Haruhiko Banno; Noriaki Suga; Yohei Okada; Manabu Ohyama; Tohru Nakagawa; Ken Kishida; Tohru Funahashi; Iichiro Shimomura; Hideyuki Okano; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2017-02-22       Impact factor: 4.849

4.  Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.

Authors:  Christopher Grunseich; Ram Miller; Therese Swan; David J Glass; Mohamed El Mouelhi; Mara Fornaro; Olivier Petricoul; Igor Vostiar; Ronenn Roubenoff; Matthew N Meriggioli; Angela Kokkinis; Robert D Guber; Maher S Budron; John Vissing; Gianni Soraru; Tahseen Mozaffar; Albert Ludolph; John T Kissel; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2018-10-15       Impact factor: 44.182

Review 5.  Gynaecomastia--pathophysiology, diagnosis and treatment.

Authors:  Harmeet S Narula; Harold E Carlson
Journal:  Nat Rev Endocrinol       Date:  2014-08-12       Impact factor: 43.330

6.  Prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy.

Authors:  Jamie A Johansen; Sandra M Troxell-Smith; Zhigang Yu; Kaiguo Mo; D Ashley Monks; Andrew P Lieberman; S Marc Breedlove; Cynthia L Jordan
Journal:  Neurodegener Dis       Date:  2010-08-04       Impact factor: 2.977

7.  Role for androgens in determination of ovarian fate in the common snapping turtle, Chelydra serpentina.

Authors:  Anthony Schroeder; Turk Rhen
Journal:  Gen Comp Endocrinol       Date:  2019-05-03       Impact factor: 2.822

Review 8.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

Review 9.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Clinical features of spinal and bulbar muscular atrophy.

Authors:  Lindsay E Rhodes; Brandi K Freeman; Sungyoung Auh; Angela D Kokkinis; Alison La Pean; Cheunju Chen; Tanya J Lehky; Joseph A Shrader; Ellen W Levy; Michael Harris-Love; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.